(Q63283118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

title

Monoclonal antibodies and therapy of human cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Armando Santoro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Fabio Malavasi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

author name string

A L Horenstein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

C Cinti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

A Gregorini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

published in

Biotechnology Advances

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

385-401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Chemotherapy targeted to tumor vasculature.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Developments with targeted enzymes in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Targeting enzymes to cancers--new developments.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Pretargeting with the affinity enhancement system for radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Human monoclonal antibodies: the emperor's new clothes?

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Strategies for expressing human antibody repertoires in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Antibody affinity maturation using bacterial surface display.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

A new era for radiolabeled antibodies in cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Bispecific antibodies for the treatment of tumours and infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Anticancer drug targets: growth factors and growth factor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Pretargeted peptide imaging and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Selection of phage antibodies by binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Positive versus negative signaling by lymphocyte antigen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Antibody phage display technology and its applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Delivery of molecular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Anticancer drug targets: approaching angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Use of rituximab, the new FDA-approved antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Immunocytokines: a promising approach to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Radioimmunotherapy of gastrointestinal cancer and glioblastomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Antibody-based immunological therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Bispecific antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Multiple event activation of a generic prodrug trigger by antibody catalysis

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

Making antibodies by phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0734-9750%2800%2900043-4

7 January 2021

10.1016/S0734-9750(00)00043-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14538101%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference